Crohn’s disease (CD) - Articles and news items

ustekinumab

NICE recommends Janssen’s Crohn’s Disease biological therapy

Industry news / 2 May 2017 / Niamh Marriott, Junior Editor

NICE has recommended Stelara (ustekinumab) in its final appraisal determination as a treatment option for adult patients with Crohn’s disease…

Crohn’s disease

Celltrion Healthcare & Pfizer’s biosimilar shows positive results in Crohn’s disease study

Industry news / 20 February 2017 / Niamh Marriott, Digital Editor

Celltrion Healthcare presented the primary outcome from its pivotal randomised controlled trial of CT-P13 (biosimilar infliximab) in Crohn’s disease.

Enterome starts Phase I Crohn’s disease trial

Industry news / 5 January 2017 / Niamh Marriott (Digital Editor)

Enterome has launched a Phase I clinical study with its lead drug candidate EB8018, a small molecule designed to block FimH, to treat Crohn’s disease…

Takeda makes €10 million equity investment in TiGenix

Industry news / 22 December 2016 / Niamh Louise Marriott, Digital Editor

TiGenix, has exercised the option granted by Takeda under the licensing agreement to make a €10 million equity investment in TiGenix…

TiGenix’s Crohn’s disease drug granted Swiss orphan drug designation

Industry news / 18 October 2016 / Niamh Louise Marriott, Digital Content Producer

Cx601 is a suspension of allogeneic adipose-derived stem cells for the treatment of complex perianal fistulas in patients with Crohn’s disease that have…

MedImmune out-licenses inflammatory diseases medicine to Allergan

Industry news / 3 October 2016 / Niamh Louise Marriott, Digital Content Producer

MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb trial for Crohn’s disease (a chronic inflammatory disease of the intestines) and is…

RedHill Biopharma receives patent approval for MS drug

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

A first Phase III study with RHB-104 for the treatment of Crohn’s disease is currently ongoing, as well as a Phase IIa proof-of-concept study for the treatment of MS…

Takeda & TiGenix announce Perianal Fistulas trial treatment results in patients with Crohn's disease

Takeda & TiGenix announce Perianal Fistulas trial treatment results for Crohn’s disease

Industry news / 2 August 2016 / Takeda Pharmaceutical Company Limited / TiGenix NV

Takeda and TiGenix announce that the results of the Phase 3 ADMIRE-CD trial investigating Cx601 have been published. Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn’s disease…

Samsung Bioepis seeks EU approval for its biosimilar adalimumab candidate, SB5

Industry news / 18 July 2016 / Victoria White, Digital Content Producer

At an estimated $4billion a year, the reference product, Humira, is among the European Union’s largest single drug expenditures…

Takeda enters into licensing agreement for ex-US rights to Cx601

Industry news / 5 July 2016 / Victoria White, Digital Content Producer

Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally for the treatment of complex perianal fistulas in Crohn’s disease…

Infliximab biosimilar Flixabi approved in the EU

Industry news / 31 May 2016 / Victoria White, Digital Content Producer

The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade…

Clinical remission data for Stelara in Crohn’s disease presented at DDW

Industry news / 25 May 2016 / Victoria White, Digital Content Producer

Data shows that a greater proportion of adult patients with Crohn’s disease receiving Stelara SC maintenance therapy were in clinical remission at one year…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+